Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21420047 | 1.00 | EPHX2 (0.34) | EPHX2MCL1TDP1BCL2CHRNB2 | |
| SCHEMBL27076710 | 1.00 | EPHX2 (0.34) | EPHX2MCL1TDP1BCL2CHRNB2 | |
| SCHEMBL15839886 | 1.00 | EPHX2 (0.34) | EPHX2MCL1TDP1BCL2CHRNB2 | |
| SCHEMBL29031623 | 0.80 | MCL1 (0.33) | EPHX2MCL1BCL2 | |
| SCHEMBL20640556 | 0.80 | EPHX2 (0.34) | EPHX2MCL1BCL2CHRNB2CHRNA3 | |
| SCHEMBL29031625 | 0.80 | MCL1 (0.33) | EPHX2MCL1BCL2 | |
| SCHEMBL20640557 | 0.80 | EPHX2 (0.34) | EPHX2MCL1BCL2CHRNB2CHRNA3 | |
| SCHEMBL21407651 | 0.80 | MCL1 (0.33) | EPHX2MCL1BCL2 | |
| SCHEMBL20640934 | 0.80 | EPHX2 (0.34) | EPHX2MCL1BCL2CHRNB2CHRNA3 | |
| SCHEMBL14697193 | 0.79 | EPHX1 (0.48) | EPHX2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300974-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210238125-A1 | Diabetes and Metabolic Syndrome Treatment with a Novel Dual Modulator of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210139504-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10975095-B2 | — | — | 2021-04-13 | — | — | US | disclosed |
| EP-3652178-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2020-05-20 | — | — | EP | disclosed |
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2019012063-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2019-01-17 | — | — | WO | disclosed |
| WO-2017004525-A1 | DIABETES AND METABOLIC SYNDROME TREATMENT WITH A NOVEL DUAL MODULATOR OF SOLUBLE EPOXIDE HYDROLASE AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| EP-1095038-B1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2003-09-03 | — | — | EP | disclosed |
| EP-0873336-B1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6200957-B1 | USEFUL FOR TREATMENT OF VARIETY OF SEX-HORMONE RELATED AND OTHER CONDITIONS IN BOTH MEN AND WOMEN | MERCK & CO., INC. | 2001-03-13 | — | — | US | disclosed |
| US-5849764-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0871624-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5780437-A | ADMINISTERING TO TREAT SEX-HORMONE RELATED DISORDERS | MERCK & CO., INC. (US) | 1998-07-14 | — | — | US | disclosed |
| US-5756507-A | TREATING SEX HORMONE RELATED DISORDERS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1997021703-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | EPHX2 286/4885MCL1 856/4885TDP1 3552/4885 |
| US-20210139504-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | EPHX2 286/4885MCL1 856/4885TDP1 3552/4885 |
| US-10975095-B2 | — | CYP1B1, UGT1A1, CYP4B1 | EPHX2 414/4885MCL1 871/4885TDP1 3903/4885 |
| US-20210238125-A1 | Diabetes and Metabolic Syndrome Treatment with a Novel Dual Modulator of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors | EPHX1, EPHX2, PPARG | EPHX2 2/4885MCL1 3407/4885TDP1 4587/4885 |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | HSD17B7, CYP11B1, CYP11B2 | EPHX2 286/4885MCL1 856/4885TDP1 3552/4885 |
| US-20240300974-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | EPHX2 286/4885MCL1 856/4885TDP1 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.